Theravance Biopharma, Inc. (TBPH)
14.33
+0.32
(+2.28%)
USD |
NASDAQ |
Mar 20, 16:00
14.34
+0.01
(+0.10%)
After-Hours: 20:00
Theravance Biopharma Research and Development Expense (Quarterly) : 7.362M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Integer Holdings Corp. | 10.11M |
| QuidelOrtho Corp. | 45.80M |
| Viatris, Inc. | 259.80M |
| Catalyst Pharmaceuticals, Inc. | 1.807M |
| Nektar Therapeutics | 29.68M |